Clinical trialNCT06770582RecruitingPhase 2Interventional

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

SponsorNational Cancer Institute (NCI)Enrollment160Non-Muscle Invasive Bladder Urothelial CarcinomaRecurrent Non-Muscle Invasive Bladder Urothelial CarcinomaStage I Bladder Cancer AJCC v8

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase II trial compares the use of pembrolizumab and radiation therapy to chemotherapy with cisplatin, gemcitabine, 5-fluorouracil or mitomycin-C and radiation therapy for the treatment of non-muscle invasive bladder cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, gemcitabine, 5-fluorouracil or mitomycin-C, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Giving pembrolizumab with radiation may kill more tumor cells than chemotherapy with radiation therapy in patients with non-muscle invasive bladder cancer.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Brian C Baumann
NRG Oncology
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

136 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada

the Research Institute of the Mcgill University Health Centre (muhc)
Montreal, Quebec, Canada
Fabio L. Cury
Recruiting
Chu de Quebec-L'Hotel-Dieu de Quebec (hdq)
Québec, Quebec, Canada
Eric Vigneault
Recruiting

United States

Highlands Oncology Group - Fayetteville
Fayetteville, Arkansas, United States
Joseph T. Beck
Recruiting
Highlands Oncology Group - Rogers
Rogers, Arkansas, United States
Joseph T. Beck
Recruiting
Highlands Oncology Group
Springdale, Arkansas, United States
Joseph T. Beck
Recruiting
Ais Cancer Center at San Joaquin Community Hospital
Bakersfield, California, United States
Luis Mariscal
Recruiting
Los Angeles General Medical Center
Los Angeles, California, United States
Lauren A. Lukas
Recruiting
Usc / Norris Comprehensive Cancer Center
Los Angeles, California, United States
Lauren A. Lukas
Recruiting
Shaw Cancer Center
Edwards, Colorado, United States
Erin Schwab
Recruiting
Helen F Graham Cancer Center
Newark, Delaware, United States
Gregory A. Masters
Recruiting
Medical Oncology Hematology Consultants Pa
Newark, Delaware, United States
Gregory A. Masters
Recruiting
Uf Health Cancer Institute - Gainesville
Gainesville, Florida, United States
Daniel V. Araujo
Recruiting
Mount Sinai Medical Center
Miami Beach, Florida, United States
Bruno R. Bastos
Recruiting
Emory Proton Therapy Center
Atlanta, Georgia, United States
Kamran Salari
Recruiting
Emory Saint Joseph'S Hospital
Atlanta, Georgia, United States
Kamran Salari
Recruiting
Emory University Hospital Midtown
Atlanta, Georgia, United States
Kamran Salari
Recruiting
Emory University Hospital/winship Cancer Institute
Atlanta, Georgia, United States
Kamran Salari
Recruiting
Grady Health System
Atlanta, Georgia, United States
Kamran Salari
Recruiting
Rush Md Anderson Cancer Center
Chicago, Illinois, United States
Dian Wang
Recruiting
Carle at the Riverfront
Danville, Illinois, United States
Daniel H. Barnett
Recruiting
Cancer Care Specialists of Illinois - Decatur
Decatur, Illinois, United States
Bryan A. Faller
Recruiting
Decatur Memorial Hospital
Decatur, Illinois, United States
Bryan A. Faller
Recruiting
Carle Physician Group-Effingham
Effingham, Illinois, United States
Daniel H. Barnett
Recruiting
Crossroads Cancer Center
Effingham, Illinois, United States
Bryan A. Faller
Recruiting
Carle Physician Group-Mattoon/charleston
Mattoon, Illinois, United States
Daniel H. Barnett
Recruiting
Carle Bromenn Medical Center
Normal, Illinois, United States
Daniel H. Barnett
Recruiting
Carle Cancer Institute Normal
Normal, Illinois, United States
Daniel H. Barnett
Recruiting
Hshs Saint Elizabeth'S Hospital
O'Fallon, Illinois, United States
Bryan A. Faller
Recruiting
Southern Illinois University School of Medicine
Springfield, Illinois, United States
Bryan A. Faller
Recruiting
Springfield Clinic
Springfield, Illinois, United States
Bryan A. Faller
Recruiting
Springfield Memorial Hospital
Springfield, Illinois, United States
Bryan A. Faller
Recruiting
Carle Cancer Center
Urbana, Illinois, United States
Daniel H. Barnett
Recruiting
Mary Greeley Medical Center
Ames, Iowa, United States
Joseph J. Merchant
Recruiting
Mcfarland Clinic - Ames
Ames, Iowa, United States
Joseph J. Merchant
Recruiting
Ui Health Care Mission Cancer and Blood - Ankeny Clinic
Ankeny, Iowa, United States
Seema Harichand-Herdt
Recruiting
Mercy Cancer Center-West Lakes
Clive, Iowa, United States
Richard L. Deming
Recruiting
Ui Health Care Mission Cancer and Blood - West Des Moines Clinic
Clive, Iowa, United States
Seema Harichand-Herdt
Recruiting
Broadlawns Medical Center
Des Moines, Iowa, United States
Seema Harichand-Herdt
Recruiting
Iowa Methodist Medical Center
Des Moines, Iowa, United States
Seema Harichand-Herdt
Recruiting
Mercy Medical Center - Des Moines
Des Moines, Iowa, United States
Richard L. Deming
Recruiting

96 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Cisplatin →Fluorouracil →Gemcitabine →Mitomycin →Pembrolizumab →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 3 Jun 2025
Primary completion: 1 Feb 2032
Completion: 1 Feb 2032
Last update posted: 18 Aug 2026
Registered enrollment: 160
Registry id: NCT06770582

Cross-registrations

Other registry (CTRP (Clinical Trial Reporting ProgramNCI-2025-00008

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.